

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Link-Asia International MedTech Group Limited

環亞國際醫療科技集團有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

FURTHER DELAY IN DESPATCH OF CIRCULAR

References are made to the announcements of Link-Asia International MedTech Group Limited (the “**Company**”) dated 13 September 2022, 14 September 2022, 5 October 2022 and 26 October 2022 in relation to, among others, (i) the Subscription and the Whitewash Waiver; and (ii) the delay in despatch of Circular (the “**Announcement(s)**”). Unless the context requires otherwise, capitalised terms used herein shall have the same meanings as defined in the Announcements.

As disclosed in the Announcement dated 26 October 2022, pursuant to Rule 8.2 of the Takeovers Code, the Circular containing, among other things, (i) details of the Subscription and the Whitewash Waiver; (ii) the recommendation of the Independent Board Committee to the Independent Shareholders; (iii) the letter of advice from independent financial adviser to the Independent Board Committee in relation to the Subscription and the Whitewash Waiver; and (iv) a notice convening the EGM was expected to be despatched to the Shareholders on or before 25 November 2022.

As at the date of this announcement, further comments on the draft Circular were received from the Executive and the Stock Exchange (collectively the “**Regulators**”). As additional time is required for the Company to update relevant information and address the comments from the Regulators on the Circular, the Company has applied for the consent of the Executive for an extension of the deadline for the despatch of the Circular to a date falling on or before 2 December 2022 and the Executive is minded to grant such consent.

By order of the Board

Link-Asia International MedTech Group Limited

Lin Dailian

Chairman and executive Director

Hong Kong, 25 November 2022

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Liu Zhiwei and Ms. Lin Xiaoshan as executive Directors; Mr. Li Huiwu, Mr. Yang Weidong and Mr. Chak Chi Shing as independent non-executive Directors.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.